Institute for Advanced Biosciences, UGA-INSERM U1209-CNRS UMR5309, Allée des Alpes, France.
Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Sachs' Children's Hospital, Stockholm, Sweden.
Allergy. 2020 Dec;75(12):3248-3260. doi: 10.1111/all.14314. Epub 2020 Apr 23.
Allergic diseases often occur in combination (multimorbidity). Human blood transcriptome studies have not addressed multimorbidity. Large-scale gene expression data were combined to retrieve biomarkers and signaling pathways to disentangle allergic multimorbidity phenotypes.
Integrated transcriptomic analysis was conducted in 1233 participants with a discovery phase using gene expression data (Human Transcriptome Array 2.0) from whole blood of 786 children from three European birth cohorts (MeDALL), and a replication phase using RNA Sequencing data from an independent cohort (EVA-PR, n = 447). Allergic diseases (asthma, atopic dermatitis, rhinitis) were considered as single disease or multimorbidity (at least two diseases), and compared with no disease.
Fifty genes were differentially expressed in allergic diseases. Thirty-two were not previously described in allergy. Eight genes were consistently overexpressed in all types of multimorbidity for asthma, dermatitis, and rhinitis (CLC, EMR4P, IL5RA, FRRS1, HRH4, SLC29A1, SIGLEC8, IL1RL1). All genes were replicated the in EVA-PR cohort. RT-qPCR validated the overexpression of selected genes. In MeDALL, 27 genes were differentially expressed in rhinitis alone, but none was significant for asthma or dermatitis alone. The multimorbidity signature was enriched in eosinophil-associated immune response and signal transduction. Protein-protein interaction network analysis identified IL5/JAK/STAT and IL33/ST2/IRAK/TRAF as key signaling pathways in multimorbid diseases. Synergistic effect of multimorbidity on gene expression levels was found.
A signature of eight genes identifies multimorbidity for asthma, rhinitis, and dermatitis. Our results have clinical and mechanistic implications, and suggest that multimorbidity should be considered differently than allergic diseases occurring alone.
过敏性疾病常合并发生(共病)。人类血液转录组研究尚未涉及共病。本研究整合了大规模基因表达数据,以寻找生物标志物和信号通路,从而解析过敏性共病表型。
在 1233 名参与者中进行了整合转录组分析,其中包括使用来自三个欧洲出生队列(MeDALL)的 786 名儿童全血的基因表达数据(Human Transcriptome Array 2.0)进行的发现阶段,以及使用来自独立队列(EVA-PR,n=447)的 RNA 测序数据进行的复制阶段。将过敏性疾病(哮喘、特应性皮炎、鼻炎)视为单病或共病(至少两种疾病),并与无疾病者进行比较。
在过敏性疾病中,有 50 个基因表达存在差异。其中 32 个基因在过敏中以前没有描述过。在哮喘、皮炎和鼻炎的所有共病类型中,有 8 个基因始终过度表达(CLC、EMR4P、IL5RA、FRRS1、HRH4、SLC29A1、SIGLEC8、IL1RL1)。所有基因在 EVA-PR 队列中均得到复制。实时定量 PCR 验证了选定基因的过表达。在 MeDALL 中,在单独的鼻炎中,有 27 个基因表达存在差异,但在单独的哮喘或皮炎中均无显著差异。共病特征与嗜酸性粒细胞相关免疫反应和信号转导有关。蛋白质-蛋白质相互作用网络分析发现,IL5/JAK/STAT 和 IL33/ST2/IRAK/TRAF 是共病中的关键信号通路。还发现了共病对基因表达水平的协同作用。
有 8 个基因的特征可以识别哮喘、鼻炎和皮炎的共病。我们的研究结果具有临床和机制意义,表明应将共病视为不同于单独发生的过敏性疾病。